CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features

Haematologica

Volumn 96, Issue 2, 2011, Pages 328-332

  Schmidt Hieber, Martin ^a   Pérez Andrés, Martin ^a   Paiva, Bruno ^a   Flores Montero, Juan ^a   Perez, Jose J ^a   Gutierrez, Norma C ^a   Vidriales, Maria Belen ^a   Matarraz, Sergio ^a   San Miguel, Jesus F ^a   Orfao, Alberto ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

CD117 expression; Lymphoid maturation; Monoclonal gammopathy; Multiparameter flow cytometry; Myeloid maturation; Normal residual plasma cells

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL MATURATION; CELLULAR DISTRIBUTION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOID PROGENITOR CELL; NEUTROPHIL; PLASMA CELL; PLOIDY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC SYSTEM; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOID CELLS; PARAPROTEINEMIAS; PLOIDIES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 79551631933     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031872     Document Type: Article

References (18)

1. Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the ckit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma. 1998;30(5-6):459-66.
2. Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res. 2008;32(3):379-82.
3. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol. 2006;6(2):107-16.
4. Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010;78(3):154-68.
5. Bravo P, Agustín BD, Bellas C, González D, Cámara C, Fuertes IF, et al. Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation. Am J Hematol. 2000;63(4):226-9.
6. Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, et al.; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with highdose therapy. J Clin Oncol. 2008;26(16): 2737-44.
7. Vakiani E, Cattoretti G, Colovai AI, Murty VV, Alobeid B, Bhagat G. CD117 expression in diffuse large B-cell lymphomas: fact or fiction? Pathol Int. 2005;55(11):716-23.
8. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-80.
9. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138(1): 12-30.
10. Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R, et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009;175(6):2416-29.
11. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
12. + plasma cells. Haematologica. 2010;95(6):1016-20.
13. Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, et al.; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369-72.
14. Mateo G, Castellanos M, Rasillo A, Gutiérrez NC, Montalbán MA, Martín ML, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005;11(10):3661-7.
15. Montero JC, López-Pérez R, San Miguel JF, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica. 2008; 93(6):851-9.
16. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutiérrez N, San Miguel JF. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol. 2003;123(5):858-68.
17. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, et al. A phase II trial of imatinib in patients with refractory/ relapsed myeloma. Leuk Lymphoma. 2006;47(1):39-42.
18. Renström J, Kröger M, Peschel C, Oostendorp RA. How the niche regulates hematopoietic stem cells. Chem Biol. Interact 2010;184(1-2):7-15.